Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161186 · ClinicalTrials.gov registry record · Phase 1
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
A Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT01161186 is a Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms that has completed, run by University of California, San Francisco. The registered enrollment target is 15 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01161186, a Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG nab-paclitaxel, gemcitabine, capecitabine
Study Locations (2)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01161186
The ClinicalTrials.gov registry entry for NCT01161186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which nab-paclitaxel, gemcitabine, capecitabine is the first listed.
NCT01161186 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Utah.
Frequently Asked Questions
What is clinical trial NCT01161186 about?
NCT01161186 is a clinical study titled "Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma". The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.
What is the current status of trial NCT01161186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-07. Estimated completion is 2012-10.
What conditions does trial NCT01161186 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Neoplasms, Adenocarcinoma.
What interventions are being tested in trial NCT01161186?
The interventions under investigation include: nab-paclitaxel, gemcitabine, capecitabine (DRUG).
Who is sponsoring clinical trial NCT01161186?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01161186 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.